AP-1 Inhibition by SR 11302 Protects Human Hepatoma HepG2 Cells from Bile Acid-Induced Cytotoxicity by Restoring the NOS-3 Expression.

The harmful effects of bile acid accumulation occurring during cholestatic liver diseases have been associated with oxidative stress increase and endothelial nitric oxide synthase (NOS-3) expression decrease in liver cells. We have previously reported that glycochenodeoxycholic acid (GCDCA) down-reg...

Full description

Bibliographic Details
Main Authors: Sandra González-Rubio, Clara I Linares, Patricia Aguilar-Melero, Manuel Rodríguez-Perálvarez, José L Montero-Álvarez, Manuel de la Mata, Gustavo Ferrín
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4973998?pdf=render
id doaj-687823b330fb4a06aabd224c01908286
record_format Article
spelling doaj-687823b330fb4a06aabd224c019082862020-11-25T01:42:17ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01118e016052510.1371/journal.pone.0160525AP-1 Inhibition by SR 11302 Protects Human Hepatoma HepG2 Cells from Bile Acid-Induced Cytotoxicity by Restoring the NOS-3 Expression.Sandra González-RubioClara I LinaresPatricia Aguilar-MeleroManuel Rodríguez-PerálvarezJosé L Montero-ÁlvarezManuel de la MataGustavo FerrínThe harmful effects of bile acid accumulation occurring during cholestatic liver diseases have been associated with oxidative stress increase and endothelial nitric oxide synthase (NOS-3) expression decrease in liver cells. We have previously reported that glycochenodeoxycholic acid (GCDCA) down-regulates gene expression by increasing SP1 binding to the NOS-3 promoter in an oxidative stress dependent manner. In the present study, we aimed to investigate the role of transcription factor (TF) AP-1 on the NOS-3 deregulation during GCDCA-induced cholestasis. The cytotoxic response to GCDCA was characterized by 1) the increased expression and activation of TFs cJun and c-Fos; 2) a higher binding capability of these at position -666 of the NOS-3 promoter; 3) a decrease of the transcriptional activity of the promoter and the expression and activity of NOS-3; and 4) the expression increase of cyclin D1. Specific inhibition of AP-1 by the retinoid SR 11302 counteracted the cytotoxic effects induced by GCDCA while promoting NOS-3 expression recovery and cyclin D1 reduction. NOS activity inhibition by L-NAME inhibited the protective effect of SR 11302. Inducible NOS isoform was no detected in this experimental model of cholestasis. Our data provide direct evidence for the involvement of AP-1 in the NOS-3 expression regulation during cholestasis and define a critical role for NOS-3 in regulating the expression of cyclin D1 during the cell damage induced by bile acids. AP-1 appears as a potential therapeutic target in cholestatic liver diseases given its role as a transcriptional repressor of NOS-3.http://europepmc.org/articles/PMC4973998?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Sandra González-Rubio
Clara I Linares
Patricia Aguilar-Melero
Manuel Rodríguez-Perálvarez
José L Montero-Álvarez
Manuel de la Mata
Gustavo Ferrín
spellingShingle Sandra González-Rubio
Clara I Linares
Patricia Aguilar-Melero
Manuel Rodríguez-Perálvarez
José L Montero-Álvarez
Manuel de la Mata
Gustavo Ferrín
AP-1 Inhibition by SR 11302 Protects Human Hepatoma HepG2 Cells from Bile Acid-Induced Cytotoxicity by Restoring the NOS-3 Expression.
PLoS ONE
author_facet Sandra González-Rubio
Clara I Linares
Patricia Aguilar-Melero
Manuel Rodríguez-Perálvarez
José L Montero-Álvarez
Manuel de la Mata
Gustavo Ferrín
author_sort Sandra González-Rubio
title AP-1 Inhibition by SR 11302 Protects Human Hepatoma HepG2 Cells from Bile Acid-Induced Cytotoxicity by Restoring the NOS-3 Expression.
title_short AP-1 Inhibition by SR 11302 Protects Human Hepatoma HepG2 Cells from Bile Acid-Induced Cytotoxicity by Restoring the NOS-3 Expression.
title_full AP-1 Inhibition by SR 11302 Protects Human Hepatoma HepG2 Cells from Bile Acid-Induced Cytotoxicity by Restoring the NOS-3 Expression.
title_fullStr AP-1 Inhibition by SR 11302 Protects Human Hepatoma HepG2 Cells from Bile Acid-Induced Cytotoxicity by Restoring the NOS-3 Expression.
title_full_unstemmed AP-1 Inhibition by SR 11302 Protects Human Hepatoma HepG2 Cells from Bile Acid-Induced Cytotoxicity by Restoring the NOS-3 Expression.
title_sort ap-1 inhibition by sr 11302 protects human hepatoma hepg2 cells from bile acid-induced cytotoxicity by restoring the nos-3 expression.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2016-01-01
description The harmful effects of bile acid accumulation occurring during cholestatic liver diseases have been associated with oxidative stress increase and endothelial nitric oxide synthase (NOS-3) expression decrease in liver cells. We have previously reported that glycochenodeoxycholic acid (GCDCA) down-regulates gene expression by increasing SP1 binding to the NOS-3 promoter in an oxidative stress dependent manner. In the present study, we aimed to investigate the role of transcription factor (TF) AP-1 on the NOS-3 deregulation during GCDCA-induced cholestasis. The cytotoxic response to GCDCA was characterized by 1) the increased expression and activation of TFs cJun and c-Fos; 2) a higher binding capability of these at position -666 of the NOS-3 promoter; 3) a decrease of the transcriptional activity of the promoter and the expression and activity of NOS-3; and 4) the expression increase of cyclin D1. Specific inhibition of AP-1 by the retinoid SR 11302 counteracted the cytotoxic effects induced by GCDCA while promoting NOS-3 expression recovery and cyclin D1 reduction. NOS activity inhibition by L-NAME inhibited the protective effect of SR 11302. Inducible NOS isoform was no detected in this experimental model of cholestasis. Our data provide direct evidence for the involvement of AP-1 in the NOS-3 expression regulation during cholestasis and define a critical role for NOS-3 in regulating the expression of cyclin D1 during the cell damage induced by bile acids. AP-1 appears as a potential therapeutic target in cholestatic liver diseases given its role as a transcriptional repressor of NOS-3.
url http://europepmc.org/articles/PMC4973998?pdf=render
work_keys_str_mv AT sandragonzalezrubio ap1inhibitionbysr11302protectshumanhepatomahepg2cellsfrombileacidinducedcytotoxicitybyrestoringthenos3expression
AT clarailinares ap1inhibitionbysr11302protectshumanhepatomahepg2cellsfrombileacidinducedcytotoxicitybyrestoringthenos3expression
AT patriciaaguilarmelero ap1inhibitionbysr11302protectshumanhepatomahepg2cellsfrombileacidinducedcytotoxicitybyrestoringthenos3expression
AT manuelrodriguezperalvarez ap1inhibitionbysr11302protectshumanhepatomahepg2cellsfrombileacidinducedcytotoxicitybyrestoringthenos3expression
AT joselmonteroalvarez ap1inhibitionbysr11302protectshumanhepatomahepg2cellsfrombileacidinducedcytotoxicitybyrestoringthenos3expression
AT manueldelamata ap1inhibitionbysr11302protectshumanhepatomahepg2cellsfrombileacidinducedcytotoxicitybyrestoringthenos3expression
AT gustavoferrin ap1inhibitionbysr11302protectshumanhepatomahepg2cellsfrombileacidinducedcytotoxicitybyrestoringthenos3expression
_version_ 1725037455900409856